

# Daniel Catovsky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9589433/publications.pdf>

Version: 2024-02-01

89  
papers

6,002  
citations

117453

34  
h-index

79541

73  
g-index

89  
all docs

89  
docs citations

89  
times ranked

5552  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. <i>Leukemia</i> , 2022, 36, 271-274.	3.3	4
2	A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia. <i>Blood Advances</i> , 2022, 6, 4224-4227.	2.5	7
3	The association between deaths from infection and mutations of the BRAF, FBXW7, NRAS and XPO1 genes: a report from the LRF CLL4 trial. <i>Leukemia</i> , 2021, 35, 2563-2569.	3.3	8
4	Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial. <i>Leukemia</i> , 2020, 34, 1760-1774.	3.3	34
5	Early clinical trials in chronic lymphocytic leukaemia in the UK. <i>British Journal of Haematology</i> , 2020, 191, 535-541.	1.2	0
6	The Clinical Presentation of CLL. <i>Hematologic Malignancies</i> , 2019, , 39-50.	0.2	2
7	Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials. <i>Blood Advances</i> , 2019, 3, 2474-2481.	2.5	25
8	Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. <i>Blood Cancer Journal</i> , 2019, 9, 1.	2.8	40
9	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <i>Blood</i> , 2018, 131, 2745-2760.	0.6	1,069
10	Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. <i>Scientific Reports</i> , 2017, 7, 41071.	1.6	31
11	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2017, 8, 14175.	5.8	75
12	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	0.6	193
13	Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia. <i>Blood</i> , 2016, 128, 2319-2326.	0.6	90
14	Evaluation of serum markers in the LRF CLL4 trial: $\hat{I}^2$ -microglobulin but not serum free light chains, is an independent marker of overall survival. <i>Leukemia and Lymphoma</i> , 2016, 57, 2342-2350.	0.6	5
15	The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial. <i>British Journal of Haematology</i> , 2016, 174, 767-775.	1.2	29
16	Genetic Predisposition to Chronic Lymphocytic Leukemia Is Mediated by a BMF Super-Enhancer Polymorphism. <i>Cell Reports</i> , 2016, 16, 2061-2067.	2.9	58
17	The long-term outcome of patients in the LRF CLL 4 trial: the effect of salvage treatment and biological markers in those surviving 10 years. <i>British Journal of Haematology</i> , 2016, 172, 228-237.	1.2	12
18	Cytochrome P450 Allele <i>CYP3A7*1C</i> Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer. <i>Cancer Research</i> , 2016, 76, 1485-1493.	0.4	28

#	ARTICLE	IF	CITATIONS
19	Long-term follow-up after purine analogue therapy in hairy cell leukaemia. Best Practice and Research in Clinical Haematology, 2015, 28, 217-229.	0.7	57
20	An unusual indication for splenectomy in hairy cell leukaemia: a report of three cases with persistent splenomegaly after chemoimmunotherapy. British Journal of Haematology, 2015, 171, 784-787.	1.2	7
21	ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. Haematologica, 2014, 99, 736-742.	1.7	69
22	A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nature Genetics, 2014, 46, 56-60.	9.4	166
23	The clinical significance of patients' sex in chronic lymphocytic leukemia. Haematologica, 2014, 99, 1088-1094.	1.7	55
24	The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood, 2013, 121, 468-475.	0.6	190
25	CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes. Haematologica, 2013, 98, 274-278.	1.7	14
26	ZAP70 Methylation Is An Independent Prognostic Biomarker For Front Line Therapy Of Chronic Lymphocytic Leukemia : Results From The UK LRF CLL4 Trial. Blood, 2013, 122, 4137-4137.	0.6	0
27	B-cell prolymphocytic leukemia and hairy cell leukemia: new advances in biology and treatment. International Journal of Hematologic Oncology, 2012, 1, 159-167.	0.7	0
28	Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. British Journal of Haematology, 2012, 159, 322-328.	1.2	69
29	Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial. Leukemia and Lymphoma, 2012, 53, 1289-1298.	0.6	28
30	Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*. British Journal of Haematology, 2012, 156, 186-195.	1.2	76
31	Deregulated Expression of HDAC9 in B-Cells Leads to Lymphoproliferative Disorders As Well As Germinal Center and Post-Germinal Center Derived Lymphomas. Blood, 2012, 120, 3505-3505.	0.6	0
32	Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leukemia and Lymphoma, 2011, 52, 75-78.	0.6	53
33	Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leukemia and Lymphoma, 2011, 52, 21-24.	0.6	65
34	Mutational Status of the <i>TP53</i> Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial. Journal of Clinical Oncology, 2011, 29, 2223-2229.	0.8	235
35	Chlorambucilâ€”Still Not Bad: A Reappraisal. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S2-S6.	0.2	35
36	Telomere Length Is An Independent Predictor of Outcome After Therapy in CLL: Results From the UKCLL4 Trial,. Blood, 2011, 118, 3884-3884.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL). <i>Blood</i> , 2011, 118, 4986-4986.	0.6	2
38	The Outcome of CLL Patients with 97% Identity to Germline Is Inferior to Other "Mutated" Cases Defined by a 98% Cut off. <i>Blood</i> , 2011, 118, 2842-2842.	0.6	0
39	Interferon as an alternative to purine analogues in the treatment of hairy cell leukaemia - response to Benzetin. <i>British Journal of Haematology</i> , 2010, 148, 665-666.	1.2	1
40	Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. <i>Haematologica</i> , 2010, 95, 1705-1712.	1.7	116
41	Regression of intracerebral lesions in T prolymphocytic leukaemia treated with intravenous deoxycoformycin. <i>European Journal of Haematology</i> , 2009, 40, 185-187.	1.1	12
42	Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. <i>British Journal of Haematology</i> , 2009, 145, 733-740.	1.2	229
43	Gene Expression Profiling Classifies Splenic Marginal Zone Lymphoma and Hairy Cell Leukemia-Variant as Related Diseases That Are Distinct From Typical Hairy Cell Leukemia.. <i>Blood</i> , 2009, 114, 3467-3467.	0.6	0
44	Patients' experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial. <i>British Journal of Haematology</i> , 2008, 143, 690-697.	1.2	45
45	Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL. <i>Leukemia and Lymphoma</i> , 2008, 49, 2108-2115.	0.6	48
46	Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL. <i>Blood</i> , 2008, 111, 5691-5693.	0.6	30
47	High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Reveals Novel Genomic Lesions in Hairy Cell Leukaemia and Hairy-Cell Leukaemia Variant. <i>Blood</i> , 2008, 112, 3136-3136.	0.6	0
48	Long-Term Follow-up of 228 Hairy Cell Leukemia Patients Treated with Pentostatin or Cladribine with 15.4 Years Median Time from Diagnosis.. <i>Blood</i> , 2008, 112, 2101-2101.	0.6	15
49	Genome-Wide Profiling of DNA Copy Number Variation in CLL Cases Lacking 17p- (TP53) or 11q- (ATM) Abnormalities Selected from the CLL4 Study. <i>Blood</i> , 2008, 112, 3140-3140.	0.6	0
50	Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. <i>Lancet</i> , The, 2007, 370, 230-239.	6.3	660
51	The changing face of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 2283-2284.	0.6	2
52	The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. <i>Cancer</i> , 2007, 110, 2240-2247.	2.0	47
53	Baseline Characteristics Associated with Quality of Life in CLL Patients Requiring Therapy.. <i>Blood</i> , 2007, 110, 2062-2062.	0.6	0
54	Disease Burden of Chronic Lymphocytic Leukemia within the European Union.. <i>Blood</i> , 2007, 110, 5151-5151.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Prognostic Factors in the UK LRF CLL4 Trial.. Blood, 2006, 108, 299-299.	0.6	14
56	Drug Sensitivity by TRAC (DiSC) Assay as a Prognostic Factor for Patient Response in Untreated CLL: Results from the UK LRF CLL4 Trial.. Blood, 2006, 108, 303-303.	0.6	1
57	The Lack of Survival Differences in Randomised Trials in CLL May Be Related to the Effect of Second Line Therapies. A Report from the LRF CLL4 Trial.. Blood, 2006, 108, 304-304.	0.6	3
58	Îµ-Chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer, 2005, 104, 2124-2132.	2.0	63
59	Long remissions in hairy cell leukemia with purine analogs. Cancer, 2005, 104, 2442-2448.	2.0	109
60	Prognostic Factors in the UK LRF CLL4 Trial.. Blood, 2005, 106, 2099-2099.	0.6	20
61	Quality of Life in the LRF CLL4 Trial.. Blood, 2005, 106, 2111-2111.	0.6	5
62	Early Results from LRF CLL4: A UK Multicenter Randomized Trial.. Blood, 2005, 106, 716-716.	0.6	27
63	Gene Expression Reveals Two Distinct Biological Groups within T-Cell Prolymphocytic Leukaemia.. Blood, 2005, 106, 4366-4366.	0.6	0
64	Comparison of IgH Gene Rearrangement Configuration between Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia Variant (HCL-v).. Blood, 2005, 106, 4997-4997.	0.6	0
65	B-Cell Prolymphocytic Leukemia (B-PLL) and Chronic Lymphocytic Leukemia (CLL) Express Distinct Genomic Profiles.. Blood, 2005, 106, 4372-4372.	0.6	0
66	Outcomes in Patients with Splenic Marginal Zone Lymphoma or Marginal Zone Leukemia/Lymphoma Treated with Immunotherapy, Chemoimmunotherapy, or Chemotherapy.. Blood, 2005, 106, 922-922.	0.6	13
67	Combinations of ZAP-70, CD38 and IgVH Mutational Status as Predictors of Time to First Treatment in CLL.. Blood, 2005, 106, 711-711.	0.6	0
68	B- Cell Chronic Lymphocytic Leukaemia Complicated by Aggressive T-Cell Lymphoma: Clinical and Molecular Analysis of a Rare Variant of Richterâ€™s Syndrome.. Blood, 2005, 106, 4999-4999.	0.6	0
69	Familial multiple myeloma. Haematologica, 2005, 90, 3-4.	1.7	1
70	CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. The Hematology Journal, 2004, 5, 145-151.	2.0	47
71	Response to Therapy and Survival in CLL Is Influenced by Genetic Markers. Preliminary Analysis from the LRF CLL4 Trial.. Blood, 2004, 104, 13-13.	0.6	18
72	ZAP-70 Expression in Chronic Lymphocytic Leukemia: Correlation with Clinical and Biological Features.. Blood, 2004, 104, 1915-1915.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Gender as a Prognostic Factor in CLL. Biological Pointers to the Improved Outcome of Women.. Blood, 2004, 104, 957-957.	0.6	4
74	B- Prolymphocytic Leukemia Shows Heterogeneous IgVH Mutational Status and Expression of ZAP-70 and CD38.. Blood, 2004, 104, 2004-2004.	0.6	0
75	Improvement of the Chronic Lymphocytic Leukemia Scoring System With the Monoclonal Antibody SN8(CD79b). American Journal of Clinical Pathology, 1997, 108, 378-382.	0.4	336
76	Polyclonal integration of HTLV-I proviral DNA in lymphocytes from HTLV-I seropositive individuals: an intermediate state between the healthy carrier state and smouldering ATL. British Journal of Haematology, 1988, 68, 169-174.	1.2	79
77	The role of ultrastructural cytochemistry and monoclonal antibodies in clarifying the nature of undifferentiated cells in acute leukaemia. British Journal of Haematology, 1988, 69, 205-211.	1.2	76
78	Current treatment of hairy cell leukaemia. European Journal of Haematology, 1988, 41, 193-196.	1.1	6
79	The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. British Journal of Haematology, 1987, 65, 23-29.	1.2	99
80	Two new cell lines from B-prolymphocytic leukaemia: Characterization by morphology, immunological markers, karyotype and Ig gene rearrangement. International Journal of Cancer, 1986, 38, 531-538.	2.3	64
81	The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia.. British Journal of Haematology, 1986, 64, 77-86.	1.2	90
82	The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. British Journal of Haematology, 1986, 63, 377-387.	1.2	159
83	Blast Crisis of Chronic Granulocytic Leukemia with Mast Cell and Basophilic Precursors. American Journal of Clinical Pathology, 1985, 83, 254-259.	0.4	48
84	Prolymphocytic leukaemia: surface morphology in 21 cases as seen by scanning electron microscopy and comparison with B-type CLL and CLL in "prolymphocytoid" transformation. British Journal of Haematology, 1984, 57, 577-584.	1.2	8
85	The effect of tetradecanoyl-12, 13-ephorbol acetate on "hairy" cells. Scandinavian Journal of Haematology, 1984, 33, 301-308.	0.0	4
86	Cytochemistry of Normal Lymphocyte Subsets Defined by Monoclonal Antibodies and Immunocolloidal Gold. Scandinavian Journal of Haematology, 1983, 30, 433-443.	0.0	18
87	The human type-C retrovirus, HTLV, in blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma. International Journal of Cancer, 1982, 30, 257-264.	2.3	578
88	Haematological Reconstitution after Autografting for Chronic Granulocytic Leukaemia in Transformation: the Influence of Previous Splenectomy. British Journal of Haematology, 1980, 45, 223-231.	1.2	26
89	Histological Study of Bone Marrow Regeneration following Chemotherapy for Acute Myeloid Leukaemia and Chronic Granulocytic Leukaemia in Blast Transformation. British Journal of Haematology, 1980, 45, 535-540.	1.2	48